Abstract
Context Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone (GH), which can increase visceral adiposity (VAT) and impair vascular function. GH releasing hormone, a dipeptidyl peptidase-4 (DPP4) substrate, stimulates GH secretion.
Objective We tested the hypothesis that DPP4 inhibition increases GH and improves glucose levels and vascular function in women with PCOS.
Methods Eighteen women with PCOS participated in a double-blinded, cross-over study. They received sitagliptin 100 mg vs. placebo daily for one month separated by an eight-week washout. During each treatment, women underwent a 75-gram oral glucose tolerance test (OGTT), assessment of vascular function and body composition. Overnight GH secretion was assessed via venous sampling every 10 minutes for 12 hours and analyzed using an automated deconvolution algorithm.
Results During OGTT, sitagliptin increased GLP-1 (p<0.001), early insulin secretion (from mean insulinogenic index 1.9±1.2 (SD) to 3.2±3.1; p=0.02) and decreased peak glucose (mean −17.2 mg/dL [95% CI −27.7, −6.6]; p<0.01). At one month, sitagliptin decreased VAT (from 1141.9±700.7 to 1055.1±710.1 g; p=0.02) but did not affect vascular function. Sitagliptin increased GH half-life (from 13.9±3.6 to 17.0±6.8 min, N=16; p=0.04) and interpulse interval (from 53.2±20.0 to 77.3±38.2 min, N=16; p<0.05) but did not increase mean overnight GH (p=0.92 vs. placebo).
Conclusions Sitagliptin decreased the maximal glucose response to OGTT and VAT. Sitagliptin did not increase overnight GH but increased GH half-life and the interpulse interval.
Precis Sitagliptin improved body composition and blood glucoses following oral glucose load in women with PCOS. Sitagliptin potentiated GH half-life but did not increase overnight GH levels.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02122380
Funding Statement
This research was supported by Vanderbilt Clinical and Translational Science Awards (CTSA) grant UL1 TR000445-06 from the NIH National Center for Advancing Translational Sciences. The Vanderbilt Hormone Assay and Analytical Services Core is supported by NIH grants DK059637 and DK020593. JKD was supported by K23HL11962 NHLBI/NIH and NJB by R01HL125426 from NHLBI/NIH.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Reprint Requests: Nancy J. Brown, MD, Phone 615-343-8701, Nancy.j.brown{at}vumc.org
Sources of Funding: This research was supported by Vanderbilt Clinical and Translational Science Awards (CTSA) grant UL1 TR000445-06 from the NIH National Center for Advancing Translational Sciences. The Vanderbilt Hormone Assay and Analytical Services Core is supported by NIH grants DK059637 and DK020593. JKD was supported by K23HL11962 NHLBI/NIH and NJB by R01HL125426 from NHLBI/NIH.
Disclosures: The authors have nothing to disclose.
Clinical Trial Registration: This study was registered at www.clinicaltrials.gov as NCT02122380 prior to enrollment of the first participant.
Data Availability
Data are available upon request.
